# Addressing Treatment Gaps in Gout

Page: https://stenobird.com/podcast/the-bio-report-1092382/addressing-treatment-gaps-in-gout
Text version: https://stenobird.com/podcast/the-bio-report-1092382/addressing-treatment-gaps-in-gout.md
Podcast: [The Bio Report](https://stenobird.com/podcast/the-bio-report-1092382)
Published: 2026-05-06T07:00:00+00:00
Episode link: https://thebioreport.podbean.com/e/addressing-treatment-gaps-in-gout/
Audio file: https://mcdn.podbean.com/mf/web/ft9n2cfr24sufzqm/BR-James_MacKay-4-6-2686tfu.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/addressing-treatment-gaps-in-gout
Duration seconds: 2193

## Resource

Gout may be one of the oldest known forms of arthritis, but it remains widely misunderstood, undertreated, and a source of silent suffering for millions of people who are often blamed for their disease rather than offered effective care. Current therapies to lower urate levels suffer from limitations and safety challenges. Crystalys Therapeutics is in late-stage development of a next‑generation urate inhibitor that is already approved in Japan and China. Crystalys CEO James Mackay discusses the biology of gout, why standard therapies often fail to get uric acid to target levels, and how the company’s next‑generation URAT1 inhibitor may fill the treatment gap and change daily life for patients living with moderate to severe gout.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-bio-report-1092382/episodes/addressing-treatment-gaps-in-gout/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-bio-report-1092382/addressing-treatment-gaps-in-gout.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.